Altimmune Inc (ALT NASDAQ) stock market data APIs
$6.9566
-0.14(-2%)
as of June 23, 2025
Try our APIs with
free plan!
Altimmune Inc Financial Data Overview
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Prev. Close
6.9566
Open
6.8146
High
7.1254
Low
6.6951
52 wk Range
3.553-11.16
Market Cap
570 M
Shares Outstanding
81 107 K
Revenue
20 000
EPS
-0.26
Beta
0.575
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Altimmune Inc data using free add-ons & libraries
Get Altimmune Inc Fundamental Data
Altimmune Inc Fundamental data includes:
- Net Revenue: 20 000
- EBITDA: -98 033 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.3417
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Altimmune Inc News
New
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
[GLP-1 related drugs newspaper headlines with hand and magnifying glass] Leading weight loss drug developers Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]), Novo Nordisk (NVO [https://see...
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Key Points Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. It could soon have company, however, as others strive to develop their own treatments. Viking T...
Altitude Group CFO steps down as company reports order growth
LONDON - Altitude Group plc (AIM:ALT), a provider of branded merchandise solutions, announced Tuesday that Chief Financial Officer Graham Feltham has resigned from the board with immediate effect to p...
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiome...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
